Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
Random assignment
n = 147
ARM A: n = 49
ARM B: n = 48
Not treated: n = 1
Patient required therapy
procedure not permitted
Tr eated: n = 48
ARM C: n = 50
Not treated: n = 1
1 patient had presence of CNS m+
Tr eated: n = 48
Tr eated: n =49
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Downloaded from http://annonc.oxfordjournals.org/ by guest on May 6, 2015
1. Crinò L, Scagliotti GV, Ricci Set al. Gemcitabine and cisplatin versus mitomycin,
ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized
phaseIIIstudyof theItalianLungCancerProject. JClinOncol 1999; 17: 3522–3530.
2. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing
three platinum-based doublets in advanced non-small-cell-lung cancer. J Clin
Oncol 2002; 20: 4285–4291.
3. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus
carboplatin versus vinorelbine plus cisplatin in the treatment of patients with
advanced non-small-cell lung cancer: a Southwest Oncology Group trial.
J Clin Oncol 2001; 19: 3210–3218.
4. Rosell R, Gatzemeier U, Betticher DCet al. Phase III randomised trial comparing
paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced
non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol
2002; 13: 1539–1549.
5. Le Chevalier T, Scagliotti GV, Natale R et al. Efficacy of gemcitabine plus
platinum chemotherapy compared with other platinum containing regimens in
advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Lung Cancer 2005; 47: 69–80.
6. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung
cancer. Br J Cancer 2002; 87: 825–833.
7. Rudd RM, Gower NH, Spiro SG et al. Gemcitabine plus carboplatin versus
mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-smallcell lung cancer: a phase III randomized study of the London Lung Cancer Group.
J Clin Oncol 2005; 23: 142–153.
8. Treat J, Belani CP, Edelman MJ et al. Arandomized phaseIII trial of gemcitabine(G)
incombination with carboplatin (C)or paclitaxel (P)versuspaclitaxel pluscarboplatin
in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC): update of the
Alpha Oncology trial (A1-99002L). ASCOAnnual Meeting 2005 (Abstr 7025).
9. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials
comparing cisplatin to carboplatin in patients with advanced non-small-cell
lung cancer. J Clin Oncol 2004; 22: 3852–3859.
10. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs GEM
plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III
randomized trial. Lung Cancer 2003; 41: 321–331.
11. Faivre S, Le Chevalier T, Monnerat C et al. Phase I-II and pharmacokinetic
study of gemcitabine combined with oxaliplatin in patients with advanced
non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13:
1479–1489.
12. Franciosi V, Barbieri R, Aitini E et al. Gemcitabine and oxaliplatin: a safe and
active regimen in poor prognosis advanced non-small cell lung cancer patients.
Lung Cancer 2003; 41: 101–106.
13. Raymond E, Chaney SG, Taamma A et al. Oxaliplatin: a review of preclinical
and clinical studies. Ann Oncol 1998; 9: 1053–1071.
14. Norton L, Day R. Potential innovations in scheduling of cancer chemotherapy.
In DeVita VT, Hellman S, Rosemberg SA (eds): Important Advances in Oncology.
Philadelphia: Lipincott Williams & Wilkins, 1991; 57–72.
15. Shepherd FA, Dancey J, Ramlau Ret al. Prospective randomized trial of
docetaxel versus best supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:
2095–2103.
Iaffaioli RV, Tortoriello A, Facchini G et al. A phase I-II study of gemcitabine
and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999;
17: 921–926.
Bajetta E, Stani SC, De Candis D et al. Preclinical and clinical evaluation of four
GEM plus carboplatin schedules as front-line treatment for stage IV non-smallcell lung cancer. Ann Oncol 2003; 14: 242–247.
Bidoli P, Stani SC, Mariani L et al. Phase I study of escalating doses of oxaliplatin
in combination with fixed dose GEM in patients with non-small cell lung cancer.
Lung Cancer 2004; 43: 203–208.
Pujol JL, Breton JL, Gervais R et al. Gemcitabine plus docetaxel for advanced
or metastatic non-small cell lung cancer: similar survival to cisplatin plus
vinorelbine and less toxicity. Cancer Treat Rev 2005; 31: 571–576.
World Health Organization. WHO Handbook for Reporting Results of Cancer
Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO 1979.
National Cancer Institute. Cancer Therapy Evaluation Program Common Toxicity
Criteria, Version 2.0. [on-line] 1998; http://ctep.info.nih.gov/reporting/index.html
(1 and 7 November 2006, date last accessed)
Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage
phase II clinical trials. Biometrics 1995; 51: 1372–1383.
Cullen M. The development of gemcitabine and carboplatin in the treatment
of non-small-cell lung cancer. Lung Cancer 2005; 50: S5–S7.
Ardizzoni A, Tiseo M, Boni L et al. CISCA(cisplatin vs. carboplatin) meta-analysis:
an individual patient data meta-analysis comparing cisplatin versus carboplatinbased chemotherapy in first-line treatment of advanced non-small cell lung
cancer (NSCLC). J Clin Oncol 2006; 24: 366S (Abstr 7011).
Natale RB. Gemcitabine-containing regimens vs other in first-line treatment of
NSCLC. Oncology 2004; 18: 27–31.
Thomas P, Robinet G, Gouva S et al. Randomized multicentric phase II study
of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small
cell lung cancer GFPC 99-01 study (Groupe francais de pneumo-cancerologie).
Lung Cancer 2006; 51: 105–114.
Sederholm C, Hillerdal G, Lamberg Ket al. Phase III trial of GEM plus carboplatin
versus single-agent GEM in the treatment of locally advanced or metastatic
non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin
Oncol 2005; 23: 8380–8388.
Danson S, Middleton MR, O’Byrne KJ. Phase III trial of gemcitabine and
carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine,
and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer
2003; 98: 542–553.
Chiappori A, Simon G, Williams C et al. Phase II study of first-line sequential
chemotherapy with GEM-carboplatin followed by docetaxel in patients with
advanced non-small cell lung cancer. Oncology 2005; 68: 382–390.
Mazzanti P, Massacesi C, Rocchi MB et al. Randomized, multicenter, phase II
study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in
patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41: 81–89.
Cappuzzo F, Novello S, De Marinis F et al. Phase II study of gemcitabine plus
oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Br J Cancer 2005; 93: 29–34.